1. Home
  2. DX vs ABCL Comparison

DX vs ABCL Comparison

Compare DX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynex Capital Inc.

DX

Dynex Capital Inc.

N/A

Current Price

$12.52

Market Cap

3.2B

Sector

Real Estate

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$10.89

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DX
ABCL
Founded
1987
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
DX
ABCL
Price
$12.52
$10.89
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$14.75
$8.40
AVG Volume (30 Days)
4.3M
6.6M
Earning Date
04-20-2026
05-11-2026
Dividend Yield
15.11%
N/A
EPS Growth
65.77
10.91
EPS
0.45
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
$28.51
N/A
Revenue Growth
N/A
160.56
52 Week Low
$11.83
$2.75
52 Week High
$14.93
$12.58

Technical Indicators

Market Signals
Indicator
DX
ABCL
Relative Strength Index (RSI) 35.71 50.98
Support Level $12.14 $10.44
Resistance Level $13.29 $12.58
Average True Range (ATR) 0.16 0.65
MACD -0.03 -0.29
Stochastic Oscillator 10.97 0.70

Price Performance

Historical Comparison
DX
ABCL

About DX Dynex Capital Inc.

Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: